FDA says BioMarin drug results in "modest" improvements


BioMarin (BMRN +8.3%) has put together a strong session after starting the day only slightly higher.

Available now are the briefing docs for next week's Vimizim Ad Com.

FDA staff characterizes the benefit conferred on Morquio A patients as "modest."

Full documents

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs